Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Total Liabilities (2020 - 2025)

GeneDx Holdings has reported Total Liabilities over the past 6 years, most recently at $215.5 million for Q4 2025.

  • Quarterly results put Total Liabilities at $215.5 million for Q4 2025, up 23.77% from a year ago — trailing twelve months through Dec 2025 was $215.5 million (up 23.77% YoY), and the annual figure for FY2025 was $215.5 million, up 23.77%.
  • Total Liabilities for Q4 2025 was $215.5 million at GeneDx Holdings, up from $201.6 million in the prior quarter.
  • Over the last five years, Total Liabilities for WGSWW hit a ceiling of $407.6 million in Q2 2021 and a floor of $163.0 million in Q3 2023.
  • Median Total Liabilities over the past 5 years was $198.4 million (2024), compared with a mean of $224.3 million.
  • Biggest five-year swings in Total Liabilities: surged 1266.33% in 2021 and later plummeted 53.72% in 2022.
  • GeneDx Holdings' Total Liabilities stood at $166.0 million in 2021, then soared by 42.92% to $237.2 million in 2022, then dropped by 19.6% to $190.7 million in 2023, then decreased by 8.71% to $174.1 million in 2024, then rose by 23.77% to $215.5 million in 2025.
  • The last three reported values for Total Liabilities were $215.5 million (Q4 2025), $201.6 million (Q3 2025), and $186.7 million (Q2 2025) per Business Quant data.